Cytokinetics Investors Weigh Safety Data From Pivotal Trial
Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targeting a Q4 FDA submission.
Cytokinetics shared important safety information from a big test of a heart medicine. When companies show real test results, investors look at whether the medicine is safe and actually works before deciding what to think about the stock.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.